Tag: Immunotherapy
Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy
Projected five-year incidence of 15.2 and 2.3 percent for solid and hematologic malignancies after CAR T-cell immunotherapy
Cancer Vaccine Safe, Induces T-Cell Responses for KRAS-Mutated Tumors
Lymph node-targeting Amphiphile vaccine is safe; correlation seen for efficacy with T-cell response
End-of-Life Treatment With Immunotherapy Increasing for Patients With Cancer
Those treated at nonacademic or low-volume facilities have higher odds of initiating therapy within one month of death
MSI-H Colorectal Cancer Rarely Recurs After Immunotherapy Cessation
88 percent of 64 patients remained without disease progression after median of 22.6 months after stopping immunotherapy
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
Addition of daratumumab to VRd results in improved progression-free survival for transplantation-eligible patients
Study Looks at Survival in Metastatic NSCLC Treated With Immunotherapy
Survival similar among racial and ethnic groups; ECOG performance status linked to survival
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
Adverse Events Up With Immune Checkpoint Blockade Added to Periop Cancer Therapy
Increase seen in incidence of grade 3 to 4 treatment-related adverse events, adverse events leading to treatment discontinuation
